FDA approves AstraZeneca's Lynparza combo for adults with BRCA-mutated prostate cancer

Katherine Lewin

News Reporter

In April, an FDA adcomm gave the thumbs up to AstraZeneca’s blockbuster PARP inhibitor Lynparza label expansion into prostate cancer — but only for patients whose …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves AstraZeneca's Lynparza combo for adults with BRCA-mutated prostate cancer

Katherine Lewin

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FDA ap­proves As­traZeneca's Lyn­parza com­bo for adults with BR­CA-mu­tat­ed prostate can­cer

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA approves AstraZeneca's Lynparza combo for adults with BRCA-mutated prostate cancer